Dexmedetomidine modulates mitochondrial dynamics to protect against endotoxin-induced lung injury via the protein kinase C-ɑ/heme oxygenase-1 signaling pathway

Biomarkers ◽  
2021 ◽  
pp. 1-32
Author(s):  
Kai Song ◽  
Jia Shi ◽  
Lina Zhan ◽  
Qiaoying Gao ◽  
Jing Yang ◽  
...  
2006 ◽  
Vol 104 (1) ◽  
pp. 101-109 ◽  
Author(s):  
Alexander Hoetzel ◽  
Daniel Leitz ◽  
Rene Schmidt ◽  
Eva Tritschler ◽  
Inge Bauer ◽  
...  

Background The heme oxygenase pathway represents a major cell and organ protective system in the liver. The authors recently showed that isoflurane and sevoflurane up-regulate the inducible isoform heme oxygenase 1 (HO-1). Because the activating cascade remained unclear, it was the aim of this study to identify the underlying mechanism of this effect. Methods Rats were anesthetized with pentobarbital intravenously or with isoflurane per inhalation (2.3 vol%). Kupffer cell function was inhibited by dexamethasone or gadolinium chloride. Nitric oxide synthases were inhibited by either N(omega)-nitro-L-arginine methyl ester or S-methyl thiourea. N-acetyl-cysteine served as an antioxidant, and diethyldithiocarbamate served as an inhibitor of cytochrome P450 2E1. Protein kinase C and phospholipase A2 were inhibited by chelerythrine or quinacrine, respectively. HO-1 was analyzed in liver tissue by Northern blot, Western blot, immunostaining, and enzymatic activity assay. Results In contrast to pentobarbital, isoflurane induced HO-1 after 4-6 h in hepatocytes in the pericentral region of the liver. The induction was prevented in the presence of dexamethasone (P < 0.05) and gadolinium chloride (P < 0.05). Inhibition of nitric oxide synthases or reactive oxygen intermediates did not affect isoflurane-mediated HO-1 up-regulation. In contrast, chelerythrine (P < 0.05) and quinacrine (P < 0.05) resulted in a blockade of HO-1 induction. Conclusion The up-regulation of HO-1 by isoflurane in the liver is restricted to parenchymal cells and depends on Kupffer cell function. The induction is independent of nitric oxide or reactive oxygen species but does involve protein kinase C and phospholipase A2.


2005 ◽  
Vol 175 (7) ◽  
pp. 4408-4415 ◽  
Author(s):  
Stuart A. Rushworth ◽  
Xi-Lin Chen ◽  
Nigel Mackman ◽  
Richard M. Ogborne ◽  
Maria A. O’Connell

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2198-2198
Author(s):  
Namita Kumari ◽  
Sergei A Nekhai

Abstract Background Recently, HIV-1 infection was shown to be efficiently inhibited in macrophages and T-cells treated with hemin that was added extracellularly 1,2. Hemin administration to humanized transgenic mice significantly reduced HIV-1 viral load 1. Suppression of HIV-1 by hemin was mediated through the induction of (HO-1)1, via a protein kinase C-dependent pathway2. The inhibitory effect of hemin could be reversed by protoporphyrin, an HO-1 inhibitor 2. Induction of heme oxygenase-1 (HO-1) by hemin was shown to inhibit HIV-1. We recently analyzed the role of HO-1 in protecting LPS-treated human macrophages against HIV-1 infection3. LPS-treated macrophages were negative for mature virions, expressed HO-1 and produced MIP1α, MIP1β and LD78β chemokines which led to a decreased CCR5 expression. Treatment with HO-1 inhibitor SnPP IX (tin protoporphyrin IX) increased HIV-1 replication and decreased secretion of MIP1α, MIP1β, and LD78β chemokines. HO-1 also affects several proteins involved in cell cycle progression, and cell cycle is critical for HIV-1 progression. Hypoxia leads to induction and stabilization of HIF-1α and is inhibitory to HIV-1 replication. NF-kB is important for basal and Tat-activated HIV-1 transcription. Here we analyzed factors involved in HIV-1 transcription affected by HO-1 expression. Results HIV-1 replication was reduced in THP1 cells treated with hemin. Subsequent treatment with hepcidin restored HIV-1 replication, suggesting that ferroportin plays a key role in the HIV-1 inhibition. Stable ferroportin knock down in THP1 cells led to the inability of hemin to inhibit HIV-1, again suggesting that ferroportin plays a key role in this process. In hemin-treated THP-1 cells, expression of p21, HIF-1α and IKBα mRNA was induced. The expression of IKBα, an inhibitor of NF-kB, reduced the level of p65 subunit of NF-kB. We obtained similar results in THP-1 cell treated with iron chelators, which also induced the expression of IKBα, HIF-1 and p21. THP-1 cells treated with hemin or iron chelators were arrested in G1 phase of cell cycle. Stable HIF-1a knockdown in promonocytic THP-1 cells increased HIV replication suggesting that HIF-1 might be a restriction factor for HIV-1. In contrast to iron chelators that inhibited enzymatic activity of CDK2 without affecting its protein level, hemin treatment reduced CDK2 expression at mRNA and protein levels. Conclusions Induction of HIF-1 regulatory pathway and iron export by ferroportin might protect hemin-treated THP-1 cells from HIV-1 infection. Additional molecular mechanisms of heme-mediated HIV-1 inhibition might also include NF-kB inhibition by IKBα and CDK2 inhibition leading to the inhibition of HIV-1 transcription. Our results point to novel therapeutics, such as the use of hemin and iron chelators, both of which are FDA approved for treatment for acute porphyries and iron overload. Acknowledgments This project was supported by NIH Research Grants 1SC1GM082325, 2G12RR003048, and P30HL107253. Literature 1. Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J Immunol. 2006;176(7):4252-4257. 2. Devadas K, Hewlett IK, Dhawan S. Lipopolysaccharide suppresses HIV-1 replication in human monocytes by protein kinase C-dependent heme oxygenase-1 induction. J Leukoc Biol. 2010;87(5):915-924. 3. Zhou ZH, Kumari N, Nekhai S, et al. Heme oxygenase-1 induction alters chemokine regulation and ameliorates human immunodeficiency virus-type-1 infection in lipopolysaccharide-stimulated macrophages. Biochem Biophys Res Commun. 2013;435(3):373-377. Disclosures: No relevant conflicts of interest to declare.


1999 ◽  
Vol 276 (5) ◽  
pp. H1493-H1501 ◽  
Author(s):  
Christi M. Terry ◽  
Jennifer A. Clikeman ◽  
John R. Hoidal ◽  
Karleen S. Callahan

Heme oxygenase-1 (HO-1), an enzyme important in protection against oxidant stress, is induced in human vascular endothelial cells by the cytokines tumor necrosis factor-α (TNF-α) and interleukin-1α (IL-1α). However, the signaling mediators that regulate the induction are not known. This study examined the involvement of protein kinase C (PKC), phospholipase A2(PLA2), calcium, and oxidants in cytokine induction of HO-1. Acute exposure to the PKC activator phorbol 12-myristate 13-acetate (PMA) stimulated HO-1 mRNA. However, prolonged exposure, which downregulates most PKC isoforms, blocked induction of HO-1 mRNA by IL-1α and TNF-α. Additionally, the phosphatase inhibitors okadaic acid and calyculin enhanced cytokine induction of HO-1. Mepacrine, a PLA2 inhibitor, prevented HO-1 induction by cytokine, suggesting a role for arachidonate, the product of PLA2hydrolysis of phospholipids, in HO-1 expression. The intracellular calcium chelator 1,2-bis(2-aminophenoxy)ethane- N, N, N′, N′-tetraacetic acid acetoxymethyl ester (BAPTA-AM) blocked cytokine induction of HO-1. Paradoxically, the calcium ionophore A-23187 prevented HO-1 induction by cytokine but not by PMA. Finally, the oxidant scavenger N-acetylcysteine inhibited HO-1 induction by cytokines. These results demonstrate that TNF-α and IL-1α induction of HO-1 requires PKC-mediated phosphorylation and PLA2 activation as well as oxidant generation.


Endocrinology ◽  
2010 ◽  
Vol 152 (2) ◽  
pp. 384-393 ◽  
Author(s):  
Chih-Ling Chang ◽  
Lo-Chun Au ◽  
Seng-Wong Huang ◽  
Ching Fai Kwok ◽  
Low-Tone Ho ◽  
...  

Abstract Heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme catabolism, has antioxidant, antiinflammatory, and antiapoptotic effects in many physiological systems. HO-1 activity in obese mice is lower than in controls, and a sustained increase in HO-1 protein levels ameliorates insulin resistance and compensatory hyperinsulinemia. In the present study, we explored the regulatory effect of insulin on HO-1 expression in 3T3-L1 adipocytes and the underlying mechanism. We investigated the time- and dose-effect of insulin on HO-1 expression in 3T3-L1 adipocytes. Using specific inhibitors acting on insulin signaling pathways, we clarified the involvement of insulin downstream signaling molecules in insulin-regulated HO-1 expression. We also investigated the involvement of microRNAs (miRNAs) in insulin-regulated HO-1 expression using microarray and real-time RT-PCR assays. In an in vivo study, we performed insulin/glucose coinfusion in rats to increase circulating insulin levels for 8 h, then measured adipocyte HO-1 expression. Insulin caused a significant increase in HO-1 expression that was time- and dose-dependent, and this effect was blocked by inhibition of phosphatidylinositol 3 (PI3)-kinase activation using LY294002 (50 μM) or of protein kinase C activation using Ro-318220 (2 μM), but not by an Akt inhibitor, triciribine (10 μM). Furthermore, incubation of 3T3-L1 adipocytes with 100 nm insulin resulted in a significant decrease in levels of the miRNAs mir-155, mir-183, and mir-872, and this effect was also blocked by pretreatment with LY294002 or Ro-318220, but not triciribine. An in vivo study in rats showed that 8 h of a hyperinsulinemic euglycemic state resulted in a significant increase in adipocyte HO-1 expression. In conclusion, insulin increases HO-1 protein expression in 3T3-L1 adipocytes via PI3-kinase and protein kinase C-dependent pathways and miRNAs down-regulation.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5560-5560
Author(s):  
Dan Ma ◽  
Jishi Wang ◽  
Qin Fang ◽  
Yan Li

Abstract Objective Resistance toward imatinib and other BCR/ABL tyrosine kinase inhibitors(TKI) remains an increasing clinical problem in the treatment of advanced stages of chronic myeloid leukemia (CML). Heme oxygenase-1 (HO-1) inhibition plus TKI were found to produce growth inhibition in imatinib-resistant K562/IM cells and in Ba/F3 cells harboring the T315I mutant of BCR/ABL. In this study, we aimed to explore the molecular mechanism of HO-1 explosive expression and relationship between HO-1 and Protein Kinase C-βII(PKC-βII) in imatinib-resistant CML cells. Methods We explored that mRNA expression of various drug-resistant-relative gene between K562 cells and K562/IM cells via high throughout screening assay detected by real-time PCR. According to the results mentioned above, relative protein expression and phosphorylation examined by western blot. And protein translocation was observed and recorded by fluorescence microscope. Cells apoptosis, reactive oxygen species(ROS) and intracellular calcium were analyzed by flow cytometry. Cells proliferation inhibition was detected by CCK-8 assay. The peripheral blood mononuclear cells(PBMNCs) were purified from 45 patients with freshly diagnosed CML or imatinib-resistant CML(including all kinds of drug-resistance involved in various of reasons). Compared the differences of mRNA expression between HO-1 and PKC-βII in those patients. Results Our results indicated that PKC-βII contributed to activation of HO-1 expression through PI3K/AKT pathway. PKC-βII phosphorylation localized to membrane from cytoplasim to activate PI3K/AKT pathway, meanwhile, the 7.8 folder higher (p<0.01) expression of HO-1 following the nucleus translocation of NF-E2–related factor 2(Nrf-2) was observed after pAKT up-regulation. The accumulation of ROS and intracellular calcium overload were reduced by HO-1 to protect cells against cytotoxicity, less apoptotic imatinib-resistant K562 cells were detected at the same concentration of imatinib(the total apoptotic rate of K562/IM:42.4%±3.3% vs. K562: 72.1%±4.1%, at the concentration of 1 μM, p<0.01). In addition, the results of HO-1 and PKC-βII mRNA expression in PBMNCs from 45 patients indicated that HO-1 activation kept positively correspondent with expression of PKC-βII in primary leukemic cells obtained from those patients. In addition, blockage of PI3K/AKT, silence of PKC-βII or HO-1 by small interfere RNA( or inhibited by targeted inhibitor) could significantly increase apoptotic rate of imatinib-resistant CML cells(the apoptotic rate of regulated expression/ natural expression: when blockage of PI3K/AKT: 1.54±0.17; silence of PKC-βII: 2.09±0.23; inhibition of HO-1: 1.87±0.12, p<0.05). Conclusion Selectively targeted-PKC-βII plus imatinib produced growth inhibition in primary leukemic cells. In summary, these data showed that HO-1 expression involved in PKC-βII activation in imatinib-treated CML cells, and targeted- PKC-βII may be the same promising novel strategy as HO-1 inhibition in imatinib resistant CML. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document